Clinical Spectrum of Immune Checkpoint Inhibitor AKI

Immune checkpoint inhibitors have revolutionized modern oncology practice across multiple cancer types. However, renal toxicities pose significant clinical dilemmas for treating physicians. Immune checkpoint inhibitor AKI represents an important complication that requires prompt recognition and accurate classification. A recent comprehensive study conducted at Korea University Anam Hospital evaluated 943 adult patients receiving immunotherapy between 2015 and 2024. The investigators identified an overall acute kidney injury incidence of 32.1% during the first twelve months of therapy. Importantly, kidney dysfunction in this setting arises from diverse pathophysiological mechanisms. These etiologies encompass both conventional insults and autoimmune phenomena. Clinicians frequently assume that renal decline during immunotherapy represents immune-mediated nephritis. Nevertheless, the study findings reveal that acute tubular necrosis occurs far more commonly than immune-mediated acute tubulointerstitial nephritis. Therefore, oncologists and nephrologists must look beyond immune-related toxicity alone when kidney function deteriorates. In addition, prompt diagnostic differentiation ensures timely therapeutic interventions while avoiding unnecessary immunosuppression. Consequently, establishing an accurate baseline renal profile remains critical for all patients initiating checkpoint inhibitor regimens.

Prevalence and Subtypes of Checkpoint Nephrotoxicity

To systematically categorize renal deterioration, investigators applied standard KDIGO criteria. Furthermore, they distinguished transient azotemia from sustained acute kidney injury based on a 72-hour recovery window. Patients who recovered baseline serum creatinine within 72 hours comprised the transient azotemia group. In contrast, sustained injury included acute tubular necrosis, urinary tract obstruction, and true immune checkpoint inhibitor-associated acute kidney injury. Among the 943 evaluated patients, acute tubular necrosis represented the most frequent subtype. Transient azotemia followed as the second most common presentation. Mechanical urinary tract obstruction also contributed meaningfully to renal complications. However, immune-mediated acute tubulointerstitial nephritis occurred in only 25 patients out of the entire cohort. This relative rarity highlights a critical clinical takeaway for practicing oncologists and nephrologists. Although immune-related nephritis generates substantial academic attention, hemodynamic disturbances and ischemic insults remain the predominant causes of renal dysfunction. Consequently, clinicians must thoroughly investigate volume depletion, sepsis, and concurrent nephrotoxic agents before attributing kidney damage solely to immunotherapy toxicity.

Distinct Risk Factor Profiles Across Etiologies

The study uncovered distinct clinical risk factor profiles across different acute kidney injury subtypes. Specifically, pre-existing chronic kidney disease and concomitant proton pump inhibitor use independently predicted immune-mediated acute tubulointerstitial nephritis. Proton pump inhibitors frequently trigger drug-induced interstitial nephritis independently, and their combination with checkpoint inhibitors likely magnifies immunological reactivity. Conversely, patients who developed acute tubular necrosis exhibited entirely different risk determinants. Hypoalbuminemia, elevated baseline C-reactive protein levels, and hepatobiliary malignancies showed robust associations with tubular necrosis. Hypoalbuminemia often reflects chronic inflammation, malnutrition, and impaired effective circulating arterial volume. Similarly, elevated C-reactive protein indicates heightened systemic inflammation, which predisposes renal tubular cells to ischemic and oxidative insults. Hepatobiliary cancers often produce complex hemodynamic shifts, obstructive jaundice, and fluid sequestration. Therefore, clinicians must stratify risk using clinical parameters rather than applying a uniform assumption to all patients. Moreover, reviewing home medication lists allows teams to discontinue unnecessary proton pump inhibitors promptly, thereby reducing autoimmune nephritis vulnerability before immunotherapy commences.

Mortality Disparities and Prognostic Value

Acute kidney injury during cancer treatment substantially influences patient survival and ongoing therapeutic viability. In this cohort, distinct subtypes exhibited markedly divergent prognostic outcomes. Notably, transient azotemia and acute tubular necrosis independently correlated with significantly higher all-cause mortality. These findings emphasize that transient elevations in serum creatinine are not benign events in oncological patients. Instead, transient azotemia often serves as a sensitive indicator of severe physiological stress, acute dehydration, or occult infection. Similarly, sustained acute tubular necrosis reflects severe systemic illness and organ dysfunction, thereby sharply decreasing survival probability. In contrast, immune-mediated nephritis demonstrated a statistically significant but modest association with mortality. However, clinicians should interpret this modest association cautiously due to the relatively small number of immune-mediated cases. Furthermore, early detection and aggressive corticosteroid administration frequently achieve kidney recovery in immune-mediated nephritis, potentially mitigating long-term mortality risks. Thus, differentiating toxic tubular necrosis from autoimmune nephritis provides vital prognostic foresight and guides shared decision-making regarding goals of care.

Diagnostic Evaluation and Management Algorithms

Accurate distinction between renal injury subtypes requires a structured diagnostic approach and tailored therapeutic intervention. When serum creatinine rises, clinicians should immediately calculate baseline trajectory and review recent nephrotoxic exposures. Initial testing should include complete urinalysis, urine sediment microscopy, urinary protein quantification, and renal ultrasonography. The presence of sterile pyuria, white blood cell casts, and mild proteinuria strongly suggests immune-mediated tubulointerstitial nephritis. Conversely, granular muddy-brown casts point toward acute tubular necrosis. Ultrasonography effectively excludes urinary obstruction, which requires urgent urological drainage. For acute tubular necrosis and transient azotemia, physicians must prioritize volume resuscitation and remove offending nephrotoxins. In contrast, confirmed or highly suspected immune-mediated nephritis requires immediate immunotherapy suspension and prompt corticosteroid therapy. International guidelines recommend initiating oral prednisone at 0.5 to 1 mg per kilogram daily for moderate cases, tapering across four to six weeks. Additionally, clinicians should de-prescribe proton pump inhibitors to prevent repeated antigenic sensitization. Ultimately, multidisciplinary collaboration between oncologists and nephrologists optimizes renal recovery while preserving essential cancer therapies.

Frequently Asked Questions

How does acute tubular necrosis differ clinically from immune-mediated nephritis during immunotherapy?

Acute tubular necrosis typically stems from ischemic insults, volume depletion, or direct nephrotoxic exposure, manifesting with muddy-brown granular casts on urinalysis. Conversely, immune-mediated nephritis represents a delayed T-cell-driven interstitial inflammation, often presenting with sterile pyuria, mild proteinuria, and eosinophilia. While tubular necrosis demands volume resuscitation and supportive hemodynamic care, immune-mediated nephritis requires withholding the checkpoint inhibitor and initiating systemic corticosteroid therapy. Consequently, distinguishing these entities prevents inappropriate immunosuppressive therapy in critically ill cancer patients.

Why does concurrent proton pump inhibitor use increase the risk of checkpoint inhibitor nephrotoxicity?

Proton pump inhibitors can trigger idiosyncratic acute interstitial nephritis by acting as hapten-like antigens within renal tubular basement membranes. When combined with immune checkpoint inhibitors, the loss of T-cell immune tolerance amplifies drug-specific hypersensitivity reactions against kidney tissue. Consequently, memory T cells become hyperactivated, exacerbating tubulointerstitial infiltration and functional decline. Clinicians should therefore reassess the absolute indication for proton pump inhibitors, systematically de-prescribing unnecessary acid suppression or substituting alternative therapies before commencing immunotherapy.

Can oncologists safely resume immune checkpoint inhibitors after a patient recovers from renal injury?

Resuming immune checkpoint inhibitors remains feasible in select patients following complete renal recovery, particularly after grade 2 nephritis. However, permanent discontinuation is generally necessary for severe, life-threatening grade 4 toxicity. Clinicians must confirm that serum creatinine returns to baseline while the patient receives minimal or no corticosteroid therapy before attempting rechallenge. Multidisciplinary evaluation by oncologists and nephrologists is crucial, as recurrent kidney injury occurs in approximately fifteen to twenty percent of rechallenged patients.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Seo YB et al. Incidence, risk factors, and mortality of acute kidney injury in patients receiving immune checkpoint inhibitors: analysis by acute kidney injury subtype. Kidney Res Clin Pract. 2026 Oct 15. doi: 10.23876/j.krcp.25.410. PMID: 42875370.


2. Gupta S, Cortazar FB, Riella LV, Leaf DE. Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Report from the 34th Acute Disease Quality Initiative (ADQI) Consensus Conference. Kidney Int. 2026;106(4):612-625.


3. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073-4126.